您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Defactinib(VS6063,PF04554878)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Defactinib(VS6063,PF04554878)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Defactinib(VS6063,PF04554878)图片
CAS NO:1073154-85-4
规格:≥98%
包装与价格:
包装价格(元)
2mg电议
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议
1g电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)510.49
FormulaC20H21F3N8O3S
CAS No.1073154-85-4
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 5 mg/mL (9.8 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)5% DMSO+50% PEG 300+5% Tween 80+ddH2O: 5mg/mL
SynonymsVS-6063; PF-04554878; VS6063; VS 6063; PF04554878; PF 04554878; PF4554878;

Chemical Name: N-methyl-4-((4-(((3-(N-methylmethylsulfonamido)pyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide

SMILES Code: O=C(NC)C1=CC=C(NC2=NC=C(C(F)(F)F)C(NCC3=NC=CN=C3N(C)S(=O)(C)=O)=N2)C=C1

实验参考方法
In Vitro

In vitro activity: In taxane-sensitive (SKOV3ip1) and taxane-resistant (SKOV3-TR) cell lines, Defactinib significantly inhibits pFAK (Tyr397) expression. The combination of Defactinib and paclitaxel synergistically decreases proliferation and increases apoptosis in SKOV3ip1, SKOV3-TR, HeyA8 and HeyA8-MDR cells. The combination of Defactinib and Y15 synergistically decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines.


Kinase Assay: Defactinib inhibited FAK phosphorylation at the Tyr397 site in a time- and dose-dependent manner. The combination of Defactinib and paclitaxel markedly decreased proliferation and increased apoptosis, which resulted in 92.7% to 97.9% reductions in tumor weight. RPPA data showed that Defactinib reduced levels of AKT and YB-1 in taxane-resistant cell lines. FAK inhibition enhanced chemosensitivity in taxane-resistant cells by decreasing YB-1 phosphorylation and subsequently CD44 in an AKT-dependent manner. In human ovarian cancer samples, nuclear FAK expression was associated with increased nuclear YB-1 expression (χ2) = 37.7; P < .001). Coexpression of nuclear FAK and YB-1 was associated with statistically significantly worse median overall survival (24.9 vs 67.3 months; hazard ratio = 2.64; 95% confidence interval = 1.38 to 5.05; P = .006).


Cell Assay: Ovarian cancer cells are treated with increasing concentrations of Defactinib for 96 hours and then subjected to the MTT assay. Results are confirmed with triplicate experiments.

In VivoIn both PTX-sensitive and PTX-resistant models, Defactinib (50 mg/kg p.o.) enhances tumor growth inhibition by paclitaxel.
Animal modelMice bearing SKOV3ip1, SKOV3-TR, HeyA8 or HeyA8-MDR tumors
Formulation & DosageDissolved in PBS; 50 mg/kg; Administered through p.o.
ReferencesJ Natl Cancer Inst. 2013 Oct 2;105(19):1485-95; Oncotarget. 2014 Sep 15;5(17):7945-59.
生物活性


Y15 and PF-04554878 decreased cell viability in a dose-dependent manner in thyroid cancer cell lines. Oncotarget. 2014 Sep 15;5(17):7945-59.


Y15 and PF-04554878 induced significant gene changes in medullary thyroid cancer TT cells. Oncotarget. 2014 Sep 15;5(17):7945-59.


Y15 and PF-04554878 decreased clonogenicity in a dose-dependent manner in papillary thyroid cancer cell lines. Oncotarget. 2014 Sep 15;5(17):7945-59.


In vitro biological effects of VS-6063 on taxane-sensitive and taxane-resistant cell lines. J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95.


In vivo effects of VS-6063 combined with paclitaxel (PTX). J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95.


VS-6063 restores YB-1–mediated paclitaxel (PTX) resistance. J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95.


VS-6063 downregulated YB-1 phosphorylation and nuclear translocation in taxane-resistant cells by an AKT-dependent pathway. J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95.